CaPtivate Pharmaceuticals

CaPtivate Pharmaceuticals is a small, private biotech firm leveraging its calcium phosphate nanoparticle technology to create novel vaccine adjuvants and delivery systems. Its platform, branded CaPtivaX for vaccines and CaPteraX for therapeutics, aims to enhance immune responses, including T-cell activation, and can be administered via parenteral or mucosal routes. The company pursues internal development programs, such as nasal and pandemic influenza vaccines, while also offering its formulation services and technology for partnership opportunities in vaccine development.

Proprietary calcium phosphate (CaP) nanoparticle platform used as a vaccine adjuvant (CaPtivaX) and therapeutic drug delivery system (CaPteraX). Supports parenteral and mucosal administration and demonstrates capacity to induce T-cell activation.

Competes against established vaccine adjuvant companies like GSK (AS series), Seqirus (MF59), and Dynavax (CpG 1018), as well as other nanotech delivery platforms. Differentiation hinges on demonstrating superior safety, efficacy (especially mucosal/T-cell response), and formulation versatility.